Introduction：Basic information about CAS 80573-04-2|Balsalazide, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Balsalazide |
|---|
| CAS Number | 80573-04-2 | Molecular Weight | 357.318 |
|---|
| Density | 1.4±0.1 g/cm3 | Boiling Point | / |
|---|
| Molecular Formula | C17H15N3O6 | Melting Point | 254-255ºC |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | balsalazide |
|---|
| Synonym | More Synonyms |
|---|
Balsalazide BiologicalActivity
| Description | Balsalazide could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway. |
|---|
| Related Catalog | Signaling Pathways >>Immunology/Inflammation >>Interleukin RelatedResearch Areas >>Inflammation/Immunology |
|---|
| Target | STAT3 IL-6 |
|---|
| In Vivo | At the endpoint, the protein production of MIP-1β, MCP-1, IL-6, and IL-10 in the colon tissues decrease in concordance with the plasma concentrations of the cytokines. The drug-treated groups reveal lower expression of p-STAT3 compared to the CAC group. In addition, BCL2 decreases and BAX increases markedly in the BSZ+VSL#3 group[1]. Balsalazide is a new 5-aminosalicylic acid (5-ASA) containing prodrug[2]. |
|---|
| Animal Admin | Mice[1] C57B/L6J mice are randomly divided into four groups: CAC group, Balsalazide (BSZ) group (300 mg/kg), VSL#3 group, and BSZ+VSL#3 group. After two weeks, the AOM/DSS model is induced by AOM injection followed by two cycles of 2% DSS[1]. |
|---|
| References | [1]. Do EJ, et al. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. J Gastroenterol Hepatol. 2016 Aug;31(8):1453-61. [2]. Kruis W, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut, 2001. 49(6): p. 783-789. |
|---|
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|
| Melting Point | 254-255ºC |
|---|
| Molecular Formula | C17H15N3O6 |
|---|
| Molecular Weight | 357.318 |
|---|
| Exact Mass | 357.096100 |
|---|
| PSA | 148.65000 |
|---|
| LogP | 1.00 |
|---|
| Index of Refraction | 1.650 |
|---|
| InChIKey | IPOKCKJONYRRHP-UHFFFAOYSA-N |
|---|
| SMILES | O=C(O)CCNC(=O)c1ccc(N=Nc2ccc(O)c(C(=O)O)c2)cc1 |
|---|
| Storage condition | 2-8℃ |
|---|
Toxicological Information
CHEMICAL IDENTIFICATION - RTECS NUMBER :
- DG4974900
- CHEMICAL NAME :
- Benzoic acid, 5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2- hydroxy-, (E)-
- CAS REGISTRY NUMBER :
- 80573-04-2
- LAST UPDATED :
- 199406
- DATA ITEMS CITED :
- 2
- MOLECULAR FORMULA :
- C17-H15-N3-O6
- MOLECULAR WEIGHT :
- 357.35
HEALTH HAZARD DATAACUTE TOXICITY DATA - TYPE OF TEST :
- LD - Lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- >2 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 9,313,1984
- TYPE OF TEST :
- LD - Lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- >4 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 9,313,1984
|
Safety Information
| Risk Phrases | R20/21/22 |
|---|
| Safety Phrases | S36/37 |
|---|
Synonyms
| BALSALAZIDE SODIUM |
| balsalazido |
| (3E)-3-({4-[(2-Carboxyethyl)carbamoyl]phenyl}hydrazono)-6-oxo-1,4-cyclohexadiene-1-carboxylic acid |
| Balsalazide |
| BALSALAZIDE DISODIUM SALT |
| 1,4-Cyclohexadiene-1-carboxylic acid, 3-[2-[4-[[(2-carboxyethyl)amino]carbonyl]phenyl]hydrazinylidene]-6-oxo-, (3E)- |
| BALSALZIDE DISODIUM |
